FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus: Clinical relevance of a discordant PET finding

NuklearMedizin

Volumn 44, Issue 6, 2005, Pages 249-255

  Stahl, Alexander ^a,b   Stollfuss, J ^a   Ott, K ^a   Wieder, H ^a   Fink, U ^a   Schwaiger, M ^a   Weber, W A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE   (Germany)

Author keywords

Adenocarcinoma; FDG PET; Oesophagus; Staging

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; ESOPHAGEAL ADENOCARCINOMA; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMAGING; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 29744451139     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625322     Document Type: Article

References (18)

1. Block MI, Patterson GA, Sundaresan RS et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64: 770-7.
2. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
3. Flamen P, Lerut A, van Cutsem E et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-10.
4. 18F-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-8.
5. 18)-FDG PET. J Nucl Med 2004; 45: 980-7.
6. Kato H, Kuwano H, Nakajima M et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94: 921-8.
7. Kneist W, Schreckenberger M, Bartenstein P et al. Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach? World J Surg 2003; 27: 1105-12.
8. Kole AC, Plukker JT, Nieweg OE et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78: 521-7.
9. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-7.
10. Luketich JD, Friedman DM, Weigel TL et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68: 1133-7.
11. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999; 72: 525-9.
12. 18F-Deoxyglucose PET for the staging of oesophageal cancer: influence of histopathological subtype and tumour grading]. Nuklearmedizin 2003; 42: 90-3.
13. Ott K, Weber WA, Fink U et al. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 2003; 27: 1035-9.
14. Rankin SC, Taylor H, Cook GJ et al. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998; 53: 659-65.
15. rd German Interdisciplinary Consensus Conference, "Onko-PET III, 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-23.
16. Schoder H, Erdi YE, Larson SM et al. PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003; 30: 1419-37.
17. Stahl A, Ott K, Weber WA et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003; 30: 288-95.
18. Wienhard K, Eriksson L, Grootoonk S et al. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr 1992; 16: 804-13.